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Summary
Background: To timely detect myelotoxicity and hepatotoxicity, laboratory monitor-
ing at 3-month intervals is advised throughout thiopurine maintenance treatment 
for IBD. However, reported incidence rates of myelotoxicity and hepatotoxicity in 
maintenance treatment are low.
Aim: To assess incidence rates and clinical consequences of myelotoxicity and hepato-
toxicity in thiopurine maintenance therapy after at least 1 year of thiopurine treatment.
Methods: Retrospective analysis of therapy adjustment for laboratory toxicity in adult 
IBD patients after 12 consecutive months of azathioprine (AZA) or mercaptopurine mon-
otherapy (ie baseline) between 2000 and 2016. Incidence rates of laboratory toxicity (ie 
myelotoxicity [leucocyte count <4.0 × 10e9/L, and/or platelet count <150 × 10e9/L] and/
or hepatotoxicity (gamma-glutamyltransferase [GGT], alkaline phosphatase [AP], ALT 
and/or AST above ULN, excluding isolated increased AST/AP]) and associated diagnostic 
procedures and complications were assessed.
Results: In total, 12.391 laboratory assessments were performed on 1132 patients 
(56% female, AZA 74%) during 3.3 years of median follow-up. Median monitoring 
frequency was 3.1 assessments/treatment year. Only 83/12.391 (0.7%) assessments 
resulted in therapy adjustment, dose reduction in 46 patients, cessation in 28 and 
allopurinol initiation in nine; risk of therapy adjustment was 1.9% per treatment year. 
Incidence rates of myelotoxicity were 7.1% (5.1% mild/1.8% moderate/0.1% severe) 
and hepatotoxicity 5.1% (3.8% mild/1.1% moderate/0.2% severe) per treatment year. 
Treatment-related complications with concurrent laboratory toxicity occurred in 12 
patients (1.1%) and would not have been prevented by monitoring.
Conclusion: Severe laboratory toxicity is uncommon after 1 year of thiopurine mon-
otherapy at 4-month monitoring intervals. Therapy adjustments are rare after de-
tection of laboratory toxicity. After 1 year of thiopurine monotherapy, laboratory 
monitoring may be lowered to less than a 4-month interval.
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1  | INTRODUC TION
Thiopurines, azathioprine (AZA) and mercaptopurine (MP), are an 
effective maintenance therapy for patients with IBD. Advantages of 
thiopurine therapy include a steroid-sparing effect, and its associa-
tion with a reduced risk of colorectal carcinoma.1-3 A recent study on 
the effect of thiopurines on the natural history of ulcerative colitis 
showed that thiopurine continuation was associated with a lower rate 
of hospital admission and a reduced risk of progression of disease ex-
tent and a colectomy.1 Adverse events (AEs) are the most important 
downside of thiopurine therapy and result in therapy withdrawal in up 
to 40% of patients, primarily within the initial months of treatment.4-6 
These AEs can be divided into dose-independent events, such as pan-
creatitis and arthralgia and dose-dependent events. The most alarm-
ing dose-dependent AEs, hepatotoxicity and myelotoxicity, warrant 
laboratory monitoring, including a full blood count (FBC) and serum 
liver enzyme tests (LTs).7 The risk of laboratory toxicity is high in the 
first year of treatment, which is reflected by high incidence rates of 
11% for myelotoxicity and 13% for hepatotoxicity.8-10 Myelotoxicity 
and hepatotoxicity rates may be reduced after the introduction of 
thiopurine S-methyltransferase (TPMT) genotype testing before and/
or assessment of drug metabolites in thiopurine therapy.7,11
Safety concerns associated with thiopurines can be attenuated by 
the early identification of toxicity through routine laboratory moni-
toring and subsequent modification of therapy.8,10-13 This potential 
benefit of laboratory monitoring should be balanced against the bur-
den for patients and associated direct and indirect healthcare costs. 
Currently, international guidelines advise an intensive laboratory moni-
toring schedule in the first 3 months of treatment.14 During subsequent 
maintenance therapy, routine laboratory monitoring at 2 to 3-month 
intervals is recommended. Laboratory toxicity is not always clinically 
relevant as it often reverses spontaneously.9,10,15,16 Also, laboratory tox-
icity usually develops within the first few months of treatment and the 
reported incidence rate maintenance treatment is low.9,10 In addition, 
leukopenia can develop at any time during treatment without preced-
ing signs of myelotoxicity.9,15 Therefore, frequent routine assessment 
of laboratory parameters in long-term maintenance thiopurine therapy 
may have a limited clinical impact. Data on therapy adjustments or di-
agnostic procedures based on toxicity found with laboratory monitor-
ing are lacking. This study aims to assess the incidence rate and clinical 
consequences of myelotoxicity and hepatotoxicity detected with the 
current laboratory monitoring regimen in IBD patients who have been 
on thiopurine maintenance therapy for more than 1 year.
2  | MATERIAL S AND METHODS
2.1 | Study design and patient selection
A retrospective cohort study was conducted in four tertiary refer-
ral centres and two teaching hospitals in the Netherlands. Adult IBD 
patients with confirmed diagnosis of Crohn's disease (CD), ulcera-
tive colitis (UC), or IBD-unclassified (IBDU), treated with AZA or MP 
between 1 January 2000 and 31 December 2016 were included after 
1 year of thiopurine treatment. Inclusion criteria were maintenance 
thiopurine monotherapy, defined as 12 consecutive months of treat-
ment, and quiescent disease, defined as clinical, systemic steroid-free 
remission without the need for step-up treatment. Exclusion criteria 
were unavailability of laboratory assessments, a known history of 
chronic liver disease (ie viral hepatitis, auto-immune hepatitis, steato-
sis, primary sclerosing cholangitis, primary biliary cholangitis or liver 
cirrhosis), treatment with concomitant immunosuppressive medica-
tion (systemic corticosteroids, methotrexate, ciclosporin, tacrolimus, 
mycophenolate mofetil and/or biological agents) and thiopurine ther-
apy for a non-IBD indication. In addition, patients with short bowel 
syndrome (<200 cm small bowel) were excluded from analysis, be-
cause of possible interference with thiopurine absorption. This study 
conformed to the principles of the Declaration of Helsinki and was 
approved by the institutional ethics review committee of the corre-
sponding centre and all participating centres as per local regulations.
2.2 | Data collection
Baseline was set at the first laboratory assessment after 1 year of thi-
opurine treatment. Data collection was completed on 31 December 
2016. The following patient characteristics were collected from the 
patient's electronic medical records: gender, weight, smoking status 
and IBD type and Montreal classification. Treatment characteristics 
included type of thiopurine, date of initiation, dosage, concomitant 
IBD medication and TPMT genotype. Laboratory results performed 
throughout maintenance thiopurine treatment (ie after 1 year of 
treatment) were recorded and screened for toxicity. Myelotoxicity 
was defined as leukopenia and/or thrombocytopenia. Leukopenia 
was classified as mild (3.0-4.0 × 10e9/L), moderate (2.0-3.0 × 10e9/L) 
and severe (<2.0 × 10e9/L). Thrombocytopenia was also classified 
as mild (100-150 × 10e9/L), moderate (50-100 × 10e9/L) and severe 
(<50 × 10e9/L). When both leukopenia and thrombocytopenia were 
detected within a laboratory assessment, myelotoxicity was graded 
based on the most severe detected value. Hepatotoxicity was defined 
as abnormal liver tests (LTs), ie an increase of alkaline phosphatase 
(AP), gamma-glutamyltransferase (GGT), alanine aminotransferase 
(ALT) and/or alanine aminotransferase (AST) above the upper limit 
of normal (ULN). Hepatotoxicity was classified into three grades ac-
cording to the Common Terminology Criteria for Adverse Events 
(CTCAE) v. 4.0.17 Grade 1 is defined as LTs between upper limit of 
normal (ULN) and 2.5xULN, grade 2 is between 2.5 and 5.0xULN and 
grade 3 is between 5.0 and 20.0xULN. In line with previous literature, 
an isolated increase in AP or AST <2.5xULN was not considered as 
hepatotoxicity as it is not necessarily a sign of liver injury.10,18 When 
more than one aberrant LT was detected within a laboratory assess-
ment, the grade of hepatotoxicity was based on the most severe de-
tected value. When myelotoxicity and hepatotoxicity were detected 
in one assessment, the severity of “combined” toxicity was based on 
the most severe detected grade. Treatment changes and/or additional 
diagnostic procedures were recorded for patients with laboratory 
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toxicity. Patients were followed until treatment cessation or end of 
follow-up on 31 December 2016. Reasons for cessation of treatment 
included disease flare warranting step-up treatment or initiation of 
therapy with systemic (glucocortico)steroids, long-term remission, 
AEs, on patient initiative, family planning or loss to follow-up.
2.3 | Outcomes
The primary outcome was therapy adjustment based on labora-
tory toxicity, defined as therapy cessation, dose reduction or addi-
tional therapy with allopurinol alongside a reduced thiopurine dose 
(LDTA). Secondary outcomes were additional diagnostic procedures 
triggered by laboratory toxicity, incidence rates of myelotoxicity 
and hepatotoxicity and laboratory toxicity-related complications. 
Additional diagnostic procedures comprised extra laboratory as-
sessments, abdominal ultrasonography, magnetic resonance im-
aging, bone marrow examination and liver biopsy. Complications 
associated with concurrent laboratory toxicity (including hospitali-
sation, surgery or infections) were classified according to the CTCAE 
(version 4.0) and categorised according to system organ class and 
severity. Severity was subdivided in grade 1 (asymptomatic or mild 
symptoms without indication for treatment or intervention), grade 2 
(moderate symptoms; local or non-invasive intervention indicated), 
grade 3 (severe medically significant symptoms, invasive treatment 
and/or hospitalisation indicated), grade 4 (life-threatening conse-
quences) or grade 5 (death related to AE). Only therapy-related clini-
cal complications were included in the analysis.
2.4 | Statistics
The primary outcome of this study was defined as therapy adjust-
ments based on laboratory toxicity. For Kaplan-Meier survival analy-
ses, patients without therapy adjustments were censored at time of 
last follow-up or treatment cessation for other reasons than labora-
tory toxicity. Characteristics between patients with and without AEs 
were compared using the chi-square test for dichotomous variables, 
and student's t tests or Mann–Whitney U tests were used for con-
tinuous variables. Univariate and multivariable Cox proportional haz-
ards models and logistic regression models were performed to assess 
risk factors of patient characteristics and laboratory covariates as-
sociated with therapy adjustments, and the time of development of 
laboratory toxicity. Variables with a P < 0.20 were included in a multi-
variate Cox proportional hazard model. Incidence rates of myelotox-
icity and hepatotoxicity were expressed as the percentage of patients 
with detected laboratory toxicity per patient per treatment year (ab-
breviated as treatment year). Cumulative incidence of myelotoxicity 
and hepatotoxicity was calculated using Kaplan-Meier estimates, 
and stratified according to the most severe value (mild, moderate or 
severe toxicity), with time to event set at the first event in the cor-
responding category of severity. Detection rates of myelotoxicity 
and hepatotoxicity were expressed as the percentage of laboratory 
assessments showing signs of toxicity. The AZA drug dose was cal-
culated into an equivalent pharmaceutical MP dose with a conver-
sion factor of 2.08 based on molecular weight and bioavailability, the 
so-called AZA-adjusted dose.19 Data are presented as median and its 
interquartile range for continuous variables when applicable. A value 
of P < 0.05 was considered to be statistically significant. All analyses 
were conducted using IBM SPSS Statistics V.22.0 (IBM).
3  | RESULTS
3.1 | Cohort characteristics
A total of 1132 IBD patients on long-term thiopurine treatment 
were included (56% female, median age 37 years (IQR 26-49). In 
total, 843 patients (74%) were treated with AZA (adjusted median 
dose 0.9 mg/kg [IQR 0.8-1.0]) and 289 patients (26%) were treated 
with MP (median dose 0.8 mg/kg [IQR 0.6-1.1]). Median follow-up 
until cessation of therapy or censoring was 3.3 years (IQR 1.7-5.6) 
(Table 1). Treatment was discontinued in 641 patients (57%) after 
median follow-up of 4.4 years (IQR 28-6.7). Main reasons for discon-
tinuation were IBD flare in 265 patients (23%), sustained remission 
in 167 patients (15%), patient initiative in 70 patients (6%) and AEs 
in 70 patients (6%). These AEs comprised clinical AEs in 29 patients 
(2.6%) (general malaise n = 11, skin reactions n = 11, arthralgia n = 4, 
other n = 3) and laboratory toxicity in 41 patients (3.5%).
3.2 | Detection rate of myelotoxicity and 
hepatotoxicity
Overall, toxicity was detected in 2.030 (16%) of 12.391 labora-
tory assessments. During follow-up, 546 patients (48%) had signs 
of toxicity in one or more laboratory assessments. No difference 
was observed in monitoring rates between patients with or with-
out laboratory toxicity (P = 0.259). Myelotoxicity was observed in 
370 patients (33%) in 1066 assessments. Overall detection rate 
of myelotoxicity was 8.6% ie 7.6% for mild myelotoxicity, 0.9% 
for moderate myelotoxicity and 0.04% for severe myelotoxicity 
(Table 2). Hepatotoxicity was present in 275 patients (24%) in 950 
assessments with an overall detection rate of 7.7% ie 6.7% for mild 
hepatotoxicity, 0.8% for moderate hepatotoxicity and 0.1% for se-
vere hepatotoxicity (Table 2).
3.3 | Incidence rate of myelotoxicity and 
hepatotoxicity
3.3.1 | Myelotoxicity
The overall incidence rate of myelotoxicity was 7.1% per treatment year, 
specifically 5.2% for mild myelotoxicity, 1.8% for moderate myelotoxic-
ity and 0.1% for severe myelotoxicity (Figure 1A). In addition to 9% of 
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patients (n = 129) who showed myelotoxicity at baseline, cumulative in-
cidence rates of myelotoxicity on maintenance thiopurine therapy were 
12% at 1 year, 24% at 3 years and 29% at 5 years of follow-up. Median 
time to the development of myelotoxicity was 6 months from base-
line (IQR 0-20). The majority of detected myelotoxicity in laboratory 
assessments was classified as mild toxicity (945/1066 assessments, 
89%) and comprised leukopenia in 97% (1032/1066 assessments). 
Concomitant allopurinol treatment was a risk factor for myelotoxicity 
when compared to patients without laboratory toxicity (HR 1.59, 95% 
CI 1.04-2.43, P < 0.034) (Table 3). A borderline significant interaction 
was observed between MP and allopurinol (P = 0.08).
3.3.2 | Hepatotoxicity
The overall incidence rate of hepatotoxicity was 5.1% per treatment 
year ie 3.8% for mild hepatotoxicity, 1.1% for moderate hepatotox-
icity and 0.2% for severe hepatotoxicity (Figure 1B). In addition to 
the 8% of patients (n = 91) who showed hepatotoxicity at baseline, 
cumulative incidence rates of patients who showed signs of hepato-
toxicity were 6% at 1 year, 14% at 3 years and 21% at 5 years of fol-
low-up. Median onset of hepatotoxicity was 9 months from baseline 
(IQR 0-26). In univariate and multivariate Cox regression analyses 
treatment with MP (HR 1.40 95% CI 1.10-1.78, P < 0.006) and con-
comitant use of allopurinol (HR 2.73 95% CI 1.56-4.79, P < 0.0001) 
were associated with an increased risk of hepatotoxicity in long-
term thiopurine treatment (Table 3). No interaction was observed 
between MP and allopurinol.
In univariate and multivariate Cox regression analyses, male 
gender (hazard ratio [HR] 1.302; 95% confidence interval [CI] 1.10-
1.54, P < 0.009), treatment with MP (HR 1.56 95% CI 1.30-1.87, 
P < 0.0001) and diagnosis of UC/IBDU (HR 1.27 95% CI 1.09-1.54, 
P < 0.003) were associated with an increased risk of laboratory 
toxicity of any type in long-term thiopurine treatment (Table 3). 
No differences in overall toxicity, myelotoxicity and hepatotoxicity 
were observed in patients with TPMT abnormalities. Notably, thio-
purine dose in patients with intermediate TPMT activity (0.78 mg/
kg ± 0.27) was significantly lower than in patients with normal TPMT 
activity (0.90 mg/kg ± 0.26) (P = 0.027).
3.4 | Clinical consequences of laboratory toxicity
3.4.1 | Therapy adjustments for toxicity
After detection of laboratory toxicity, therapy adjustments were 
performed in 83 patients (7.3%) after a median follow-up time of 
1.8 years (IQR 0.5-3.5). Overall, 0.7% (83/12.391) of laboratory as-
sessments in this cohort resulted in a therapy adjustment. These 
therapy adjustments comprised therapy cessation (n = 28, 34%), 
dose reductions (n = 46, 55%) and switch to LDTA therapy (n = 9, 11%) 
(Table 4). Reasons for therapy cessation in these 28 patients were 
myelotoxicity (n = 14), hepatotoxicity (n = 9) and combined toxicity 
TA B L E  1   Baseline Characteristics
 N = 1132
Male sex, n (%) 500 (44)
Age (y), median [IQR] 37 [26-49]
Age at IBD diagnosis (y), median [IQR] 26 [20-36]
Weight (kg), median [IQR]a  73 [64-85]
Diagnosis, n (%)
Ulcerative colitis 363 (32)
Crohn's disease 736 (65)
IBD unclassified 33 (3)
CD—montreal age at diagnosis, n (%)
A1 <17 y 93 (13)
A2 17-40 y 508 (69)
A3 >40 y 135 (18)
CD—montreal localisation, n (%)
L1 ileal 239 (32)
L2 colonic 162 (22)
L3 ileocolonic 335 (46)
L4 upper GI disease 47 (6)
Perianal involvement 192 (26)
CD—montreal disease behaviour
B1 nonstricturing, nonpenetrating 383 (52)
B2 stricturing 212 (29)
B3 penetrating 141 (19)
UC—Montreal disease extenta,b 
E1 proctitis 27 (7)
E2 left-sided 123 (33)
E3 extensive colitis 228 (60)
History of IBD related surgery, n (%) 334 (30)
Current smokers, n (%)a  241 (21)
Thiopurine therapy
AZA 843 (74)
MP 289 (26)
Thiopurine dose (mg/kg), median [IQR]a,c 
AZA, adjustedd  0.9 [0.8-1.0]
MP 0.8 [0.6-1.0]
Concomitant IBD medication, n (%) 481 (42)
5-ASA 382 (34)
Allopurinol + AZA/Allopurinol + MP 57 (5)/42 (4)
TPMT genotype, n (%)
Normal 163 (14.4)
Heterozygote mutation 29 (2.6)
Homozygote mutation 1 (0.1)
Unknown 939 (82.9)
Note: Abbreviations: 5-ASA, 5-Aminosalicylic acid;AZA, azathioprine; 
IBD, inflammatory bowel disease; IQR, interquartile range; kg, 
kilogram; mg, milligram; MP, mercaptopurine; TPMT, thiopurine 
S-methyltransferase.
aLimited data for weight, n = 1124; for Montreal disease extent, n = 369; 
for smoking status n = 1020; for thiopurine dose, n = 1124; for TPMT 
genotype, n = 193. 
bCombined for UC/IBDU. 
cExcluding patients with concomitant use of allopurinol (n = 99). 
dAdjusted AZA drug dose represents the equivalent pharmaceutical MP 
dose with a conversion factor of 2.08. 
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(n = 5). Dose reductions were performed for myelotoxicity in 38/46 
patients (83%), hepatotoxicity in 7/46 (15%) patients and combined 
toxicity in 1/46 patients (2%). Treatment with LDTA was initiated for 
hepatotoxicity in 6/9 (67%) patients and for myelotoxicity in 3/9 pa-
tients (33%). The overall incidence rate for treatment adjustment in 
patients on maintenance thiopurine treatment after detected labo-
ratory toxicity was 1.9% per treatment year. Cumulative incidence 
rate of therapy adjustments were 2.5% at 1 year, 6.2% at 3 years, 
8.9% at 5 years and 15.4% at 10 years of follow-up (Figure 2). A 
higher thiopurine dose (HR 3.1 95% CI 1.5-6.4, P < 0.004), higher an-
nual monitoring frequency (HR 1.01 95% CI 1.00-1.01, P < 0.0001) 
and higher number of aberrant assessments (HR 1.04 95% CI 1.04-
1.05, P < 0.0001) were independently associated with therapy ad-
justments. No correlation was observed between annual monitoring 
rate and the number of aberrant assessments (Spearman correlation 
R = 0.09, P = 0.762).
3.4.2 | Monitoring rate
The median monitoring frequency was 3.1 laboratory assessments 
per treatment year (IQR 2.2-3.9) with a slight decreasing trend in 
monitoring rate over time, ranging from 3.1 assessments in the 
first year of follow-up (monitoring interval 3.9 months) to 2.0 as-
sessments per year (monitoring interval 6.0 months) after 6 years 
of follow-up. The mean monitoring interval in patients receiving 
a therapy adjustment (3.3 months, SD 1.8) was shorter (ie more 
stringent) than in patients without an adjustment (4.1 months, SD 
 
Patients
n = 1132
Overall assessments
n = 12 874
Median monitoring frequency/treatment year, 
n (IQR)
3.1 [2.2-3.9] —
Detection of laboratory toxicity, n (%) 546 (48.2) 2030 (16.4)
Myelotoxicity, n (%) 370 (32.7) 1066 (8.6)
Mild 284 (25.1) 945 (7.6)
Moderate 82 (7.2) 116 (0.9)
Severe 4 (0.4) 5 (0.04)
Hepatotoxicity, n (%) 275 (24.3) 950 (7.7)
Mild 229 (20.2) 836 (6.7)
Moderate 38 (3.4) 101 (0.8)
Severe 8 (0.7) 13 (0.1)
Abbreviation: IQR, interquartile range.
TA B L E  2   Detection rate of laboratory 
toxicity
F I G U R E  1   incidence rate of laboratory toxicity. Cumulative incidence of laboratory toxicity, stratified according to severity of 
myelotoxicity (A) or hepatotoxicity (B). A, Patients were categorised based on the most severe value of myelotoxicity detected during 
follow-up, with time to event set at first event in the corresponding category of severity. The black area represents severe myelotoxicity 
(n = 6); the dark grey area represents moderate myelotoxicity (n = 83); the grey area represents mild myelotoxicity (n = 282); the light grey 
area represents patients without myelotoxicity (n = 761). B, Patients were categorised based on the most severe value of hepatotoxicity 
detected during follow-up, with time to event set at first event in the corresponding category of severity. The black area represents severe 
hepatotoxicity (n = 8); the dark grey area represents moderate hepatotoxicity (n = 38); the grey area represents mild hepatotoxicity (n = 253); 
the light grey area represents patients without hepatotoxicity (n = 833)
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2.1, P < 0.0001). Also, the mean monitoring interval in patients 
receiving a therapy adjustment was shorter than in patients with 
laboratory toxicity but without an adjustment (4.2 months, SD 
2.0, P < 0.0001). No difference was observed in the mean moni-
toring interval in patients with laboratory toxicity (4.0, SD 2.0) and 
patients without toxicity (4.1, SD 2.2) (P = 0.757). In patients re-
ceiving a therapy adjustment, the antecedent-monitoring interval 
was not significantly different from the mean monitoring interval 
(3.8 months [SD 3.7] vs. 3.3 months [SD 1.8], P = 0.154). When com-
paring the incidence rate of toxicity in patients on the most strin-
gent monitoring regime (upper quartile [mean monitoring interval 
2.3 months]) with patients on the most liberal monitoring regime 
(in the lower quartile [mean monitoring interval 6.3 months]) no 
differences were observed in overall laboratory toxicity. However, 
the incidence rates of moderate leukopenia and severe hepatotox-
icity were higher in patients on a stringent monitoring regimen than 
in patients on a liberal monitoring regimen (12% vs 4.2%, P = 0.001) 
(5% vs 0%, P = 0.025). Details are depicted in Table 5. Cumulative 
incidence rate of therapy adjustments throughout follow-up was 
higher in patients on a stringent monitoring regimen than on a lib-
eral monitoring regimen (Figure S1).
3.4.3 | Diagnostic procedures
Additional diagnostic procedures following established laboratory 
toxicity were performed in 154 aberrant laboratory assessments 
(7.6%) in 111 patients (9.8%). Overall, 1.2% of all assessments re-
sulted in additional diagnostic procedures (Table 4). Most physicians 
followed-up on detected toxicity through extra laboratory assess-
ments (121 assessments in 86 patients), and 55% of these additional 
assessments were triggered by myelotoxicity. Ultrasound was per-
formed after established hepatotoxicity in 27 patients (2.4%). No 
cases of nodular regenerative hyperplasia were reported.
3.4.4 | Complications
Clinical treatment-related complications with concurrent labo-
ratory toxicity were detected in 12 patients (1.1%) in this cohort. 
The incidence rate of treatment-related complications with concur-
rent laboratory toxicity was 0.27% per treatment year (Table 4). 
Details on treatment-related complications are depicted in Table 6. 
Complications were more often observed in patients treated with 
MP than in AZA-treated patients (n = 6, 2.1% versus n = 6, 0.7%, 
P = 0.015). Complication rate was higher in patients on a stringent 
monitoring regimen than in patients on a liberal monitoring regimen 
(2.8% vs 0.4%, P = 0.019) (Table 5). Stringent monitoring remained 
associated with a higher complication rate when excluding all labo-
ratory assessments after the onset of complications. Strikingly, 3/12 
patients (25%) developed mild myelotoxicity, 1/12 (13%) patients 
developed moderate myelotoxicity prior to complications and 8/12 
patients (67%) presented with clinical symptoms and had no signs of 
toxicity in the preceding laboratory assessments. Five of these eight 
patients received stringent laboratory monitoring. No mortality was 
observed.
4  | DISCUSSION
Frequent laboratory monitoring is advised throughout thiopurine 
maintenance treatment to detect myelotoxicity and hepatotoxicity. 
However, laboratory toxicity usually develops within the first few 
months of treatment and the reported incidence rate in maintenance 
treatment is low. This large cohort study has demonstrated that cur-
rent laboratory monitoring regimen has limited value in patients on 
TA B L E  4   Clinical consequences of laboratory toxicity
 
Patients
n = 1.132
Laboratory 
assessments
n = 12.391
Therapy adjustments, n (%) 83 (7.3) 83 (0.7)
Cessation 28 (2.5) 28 (0.2)
Dose reductionb  46 (4.1) 46 (0.4)
LDTA therapy 9 (0.8) 9 (0.1)
Median time to adjustment, IQR 1.8 [0.5-3.5] —
Indication therapy adjustment, n (%)
Myelotoxicity 55 (3.0) 55 (0.4)
Mild/moderate/severe 17/36/2  
Hepatotoxicity 22 (3.9) 22 (0.2)
Mild/moderate/severe 14/6/2  
Myelotoxicity and 
hepatotoxicity
6 (0.4) 6 (0.05)
Mild/moderate/severe 2/3/1  
Diagnostic procedures, n (%) 111 (9.8) 154 (1.2)
Laboratory assessmenta  86 (7.6) 121 (1.0)
Ultrasounda  19 (1.8) 22 (0.2)
MRI/MRCP 6 (0.5) 6 (0.05)
Ultrasound and liver biopsyb  5 (0.4) 5 (0.04)
Indication diagnostic procedure, n (%)
Myelotoxicity 56 (4.9) 67 (0.5)
Hepatotoxicity 47 (4.2) 77 (0.6)
Myelotoxicity and 
hepatotoxicity
8 (0.7) 10 (0.1)
Complications, n (%) 12 (1.1) 12 (0.1)
Infections 7 (0.6) 7 (0.06)
Blood and lymphatic system 4 (0.4) 4 (0.03)
Gastro-intestinal disorders 1 (0.1) 1 (0.01)
Note: Complications included 6 grade 1 complications, 9 grade 2 
complications and 11 grade 3 complications.
Abbreviations: IQR, interquartile range; MRCP, Magnetic Resonance 
Cholangio-Pancreatography; MRI, magnetic resonance imaging.
a13 patients received extra laboratory assessments and ultrasound. 
bPerformed within a trial. 
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thiopurine maintenance monotherapy for at least 1 year. Although 
the incidence of myelotoxicity was 7.1% and of hepatotoxicity 5.2% 
per treatment year, laboratory assessments had little impact on clini-
cal decision making. Only 0.7% of laboratory assessments resulted 
in therapy adjustments, and only 1.4% to further diagnostic proce-
dures. Furthermore, severe treatment-related complications, such 
as infection and hospitalisation, attributed to concurrent laboratory 
toxicity are rare and these complications were not prevented with 
F I G U R E  2   Cumulative incidence of 
therapy adjustments during thiopurine 
treatment for laboratory toxicity
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Cessation 0 13 21 25 28 28 28 
Dose reduction 0 27 38 43 44 46 46 
9988430LDTA
 
Patients
n = 1132
Liberal 
monitoring
n = 283
Stringent 
monitoring
n = 283 P value
Median monitoring rate/
treatment year, n (IQR)
3.1 [2.2-3.9] 1.8 [0.0-2.0] 4.8 [4.3-6.3]  
Mean monitoring interval 
(mo), (SD)
4.1 (2.1) 6.3 (2.5) 2.3 (1.3) <0.0001
Detection of laboratory 
toxicity, n (%)
546 (48.2) 117 (41.3) 136 (48.0) 0.128
Myelotoxicity, n (%) 370 (32.7) 75 (26.5) 100 (35.3) 0.023
Mild 284 (25.1) 63 (22.3) 65 (23.0) 0.841
Moderate 82 (7.2) 12 (4.2) 34 (12.0) 0.001
Severe 4 (0.4) 0 (0.0) 1 (0.4) 0.317
Hepatotoxicity, n (%) 275 (24.3) 51 (18.0) 69 (24.4) 0.081
Mild 229 (20.2) 45 (15.9) 53 (18.7) 0.347
Moderate 38 (3.4) 7 (2,5) 11 (3.9) 0.338
Severe 8 (0.7) 0 (0.0) 5 (1.8) 0.025
Treatment-related 
complications
12 (1.1) 1 (0.4) 8 (2.8) 0.019
Note: Liberal monitoring group comprises the lower quartile (lowest monitoring rate/treatment 
year) of the study population. Stringent monitoring group comprises the upper quartile (highest 
monitoring rate/treatment year) of the study population. P values concern differences between 
liberal and stringent monitoring. Treatment-related complications comprised complications 
associated with concurrent laboratory toxicity.
Abbreviations: IQR, interquartile range; SD, standard deviation.
TA B L E  5   Detection rate of laboratory 
toxicity stratified for monitoring rate
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current monitoring regimen as the majority of cases were not pre-
ceded by laboratory toxicity in previous assessments.
The incidence of myelotoxicity and hepatotoxicity is line with 
previous studies, although there is no universal standard definition 
of laboratory toxicity, and small sample size or short follow up in 
previou studies for comparison.20-22 Myelotoxicity incidence in our 
study of 7.1% per treatment year of follow-up is based on stringent 
criteria and ranged from 5.1% for mild myelotoxicity, 1.8% for mod-
erate myelotoxicity to 0.1% for severe myelotoxicity. Myelotoxicity 
incidence was evaluated in a review of studies, in which myelotox-
icity definition varied from leucocyte count of <2.0 × 10e9/L to 
< 4.5 × 10e9/L. As expected, a higher incidence rate of 11% in the 
first year of treatment was reported than in our study. Nevertheless, 
the overall range of incidence rate of myelotoxicity incidence of 
3%-8% per treatment year is compatible with our findings for main-
tenance treatment.9
In our study, hepatotoxicity incidence was 5.1% per treatment 
year. While incidence rates of 0%-17% have been reported in other 
studies, possibly attributable to the heterogeneity of definitions, our 
findings are in line with large cohort studies that have reported in-
cidence rates of 4% and 7%.8,20,23,24 Furthermore, the moderate to 
severe hepatotoxicity rate of 1.3% per treatment year in our cohort 
is in line with the rate of 1% per treatment year in other studies.8,10
In this study, the most stringent monitoring regimen was associ-
ated with increased incidence rates in moderate myelotoxicity and 
severe hepatotoxicity compared to the most liberal monitoring regi-
men. These results should be interpreted with caution, as the causal 
relation is unclear. The probability of detecting toxicity will increase 
with more frequent monitoring. Yet, abnormal laboratory values will 
urge physicians to increase the monitoring frequency to follow-up 
on toxicity. Thus, it cannot be concluded that more frequent moni-
toring is more likely to pick up toxicity, or that previously established 
toxicity increases the monitoring frequency without direct clinical 
consequences.
In our study, fewer therapy adjustments were made to thiopu-
rine treatment as a result of laboratory toxicity than were reported 
in other studies.25-28 Our study focused on the consequences of lab-
oratory monitoring after 1 year of maintenance therapy in routine 
clinical practice and not on the consequences of laboratory find-
ings shortly after initiation of thiopurines. In our study, laboratory 
toxicity resulted in therapy adjustment in 7% of patients during fol-
low-up compared to reported rates of up to 15% in other studies. 
Furthermore, only 2.8% of patients in our cohort had to be with-
drawn from therapy because of laboratory toxicity compared to 6%-
13% of patients in other studies.25-28 In line with the high risk of 
laboratory toxicity after the start of thiopurines compared to main-
tenance treatment, these results indicate that therapy withdrawal 
due to laboratory toxicity usually occurs within the first months of 
treatment rather than during maintenance treatment.8,12,23
Our study has shown that mild toxicity is often disregarded in 
clinical practice with respect to additional diagnostic procedures. 
Laboratory results may have been disregarded because of a pre-
sumed low association between mild myelotoxicity and increased 
risk of infections, and possibly favourable outcome of mild leukope-
nia on therapeutic effectiveness of thiopurines.29
A low risk of laboratory toxicity-associated complications was 
observed. Similarly, mild hepatotoxicity was often disregarded in 
our cohort probably because the association of transient hepato-
toxicity with chronic liver disease is questionable. Laboratory tox-
icity-associated complications were detected in 1% of patients in 
our cohort. Only 33% of patients had signs of laboratory toxicity 
in previous assessments. We observed that 67% of these patients 
received stringent laboratory monitoring (upper quartile [highest] 
annual monitoring rate of the study population). Treatment-related 
complications were more often observed in patients who received 
stringent monitoring than in those who received more liberal mon-
itoring (lower quartile annual monitoring rate). As such, stringent 
monitoring does not prevent myelotoxicity-related or hepatotoxic-
ity-related complications. These observations are of considerable 
significance as the clinical impact of detecting laboratory toxicity in 
maintenance therapy is low, and thus routine monitoring is of limited 
benefit.
Mercaptopurine was found to be associated with a higher risk 
of myelotoxicity than AZA.23,30 This finding may be attributed to 
higher dosing of MP than AZA in IBD patients, because of little vari-
ation in pharmaceutical dosages in MP tablets and relatively higher 
recommended dose in official clinical guidelines than for AZA when 
correcting for bioavailability.30 This association was not confirmed 
in maintenance treatment in our cohort, presumably because of low 
dosing of thiopurines in general and MP in particular (lower dosing 
 
Total
n = 1132 Myelotoxicity Hepatotoxicity
Myelotoxicity + 
Hepatotoxicity
Cytomegalovirus 
infection, n (%)
6 (0.5) 0 (0.0) 5 (0.4) 1 (0.1)
Blood transfusiona , n (%) 2 (0.2) 2 (0.2) 0 (0.0) 0 (0.0)
Hospital admission for 
gastroenteritis, n (%)
2 (0.2) 2 (0.2) 0 (0.0) 0 (0.0)
Jaundiceb , n (%) 1 (0.1) 0 (0.0) 1 (0.1) 0 (0.0)
aPatients received a transfusion with packed red blood cells or iron for pancytopenia. 
bPatient at stable thiopurine dose presented with jaundice and hepatotoxicity after weight loss due 
to gastric sleeve surgery. 
TA B L E  6   Clinical treatment-related 
complications with concurrent laboratory 
toxicity
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than recommended in guidelines). In line with previous studies, MP 
was associated with hepatotoxicity (HR 1.40) in our cohort. This may 
well be influenced by the percentage of MP users (15%) receiving 
concomitant therapy with allopurinol. Patients treated with LDTA 
showed higher detection rates of hepatotoxicity in multivariate anal-
ysis but this interaction was not confirmed by statistical analysis. 
However, the likelihood of detecting hepatotoxicity in patients on 
LDTA is higher because some patients possibly started on allopuri-
nol shortly before inclusion in the study and hepatotoxicity had not 
normalised in the course of combination therapy.
To our knowledge, our study is the first to describe the conse-
quences of laboratory monitoring throughout thiopurine mainte-
nance monotherapy in a large real-life cohort. Limitations relate 
mostly to the retrospective nature of this study. Firstly, we may 
have underestimated the incidence of laboratory toxicity because 
prospectively identified time points were not evaluated. True my-
elotoxicity can only be identified when a full blood count is com-
pleted. In addition, the absolute neutrophil count seems to be an 
important haematologic value in assessing susceptibility to infec-
tions.31 As neutrophils were not routinely measured, transient ep-
isodes of myelotoxicity may not have been recorded. On the other 
hand, all detected laboratory toxicity was attributed to thiopurine 
therapy but other medication or viral infections are also associated 
with myelotoxicity.32,33 Also, an increased risk of hepatotoxicity 
has been reported in IBD associated with other causal factors than 
thiopurine use, such as fatty liver disease.24 Patients with a known 
history of liver disease were excluded in the analysis, but undiag-
nosed fatty liver disease in the patient population cannot be ruled 
out. High levels of the active thiopurine metabolite 6-thioguanine 
nucleotides are associated with myelotoxicity, and the byproducts 
6-methyl mercaptopurine ribonucleotides are associated with both 
myelotoxicity and hepatotoxicity.34,35 Considerations of thiopurine 
metabolite levels and adverse events are hampered because thiopu-
rine metabolites were not routinely measured and thus not included 
in the analysis. Secondly, data from six hospitals were included and 
both cessation and dose reductions were left to the discretion of 
the treating physician. Thus, the monitoring regimen and the clinical 
consequences after toxicity detection reflect the daily practice of 
these physicians. A clinician's motivation to perform therapy adjust-
ments or diagnostic procedures could be influenced by experience 
or patient-related factors. It is likely that repeated detection of lab-
oratory abnormalities led the treating physician to adjust treatment. 
In addition, both patients and physicians influenced compliance to 
laboratory monitoring regimen. Thirdly, evaluation of clinical con-
sequences of laboratory toxicity was hampered by the inability to 
discriminate between routine laboratory assessment for monitoring 
thiopurine therapy and laboratory assessments requested by other 
clinicians. This might also have led to overestimation of the moni-
toring frequency. Finally, almost 75% of patients were followed in a 
referral centre, and thus our population probably includes patients 
with a more complicated disease course or more comorbidity with a 
possible increased risk of laboratory toxicity. An important remark 
is that our results apply to patients on thiopurine monotherapy. The 
risk of laboratory toxicity in patients on combination therapy with 
biologic agents was not investigated, and the risk in this population 
may be higher.36
As thiopurine-induced laboratory toxicity occurs more frequently 
in the initial months of therapy, strict laboratory monitoring of the 
blood count and LTs in the first year of treatment as recommended 
in current guidelines seems justified.9,10 Regular laboratory monitor-
ing is recommended at 2-3 months intervals throughout maintenance 
thiopurine treatment.16,22 These recommendations are largely based 
on concern about possible complications following late-onset toxic-
ity, especially leukopenia. However, the (cost-) effectiveness of this 
schedule is not evidence-based.15,16 Laboratory monitoring practices 
in this large real-life cohort were more liberal than recommended in 
the ECCO guideline; at 4-month intervals (our study) vs at 2-3 months 
intervals (ECCO guideline). The results of our study demonstrate that 
after 1 year of thiopurine treatment, monitoring at 4-month intervals 
rarely leads to therapy adjustments and more importantly is rarely as-
sociated with treatment-related complications. Also, (frequent) mon-
itoring after 1 year of treatment does not seem to prevent laboratory 
toxicity-related complications, as preceding laboratory assessments 
were unremarkable in 67% of cases. Therefore, a firm conclusion 
can be drawn that the recommended monitoring frequency may be 
reduced to an interval of less than 4 months. We speculate that a 
monitoring regimen at 6-month intervals is sufficient in patients 
after 1 year of thiopurine treatment. This assumption is supported by 
the small number of complications in patients on the least frequent 
monitoring regimen (ie lower quartile based on annual in patients 
monitoring frequency). Also, we hypothesise that reducing labora-
tory monitoring to 6-month intervals decreases patient burden and 
healthcare costs (Supplementary Data 1). In order to confirm that lab-
oratory monitoring at 6-month intervals is non-inferior to 4-month 
intervals, prospective evaluation in an impractically large study pop-
ulation with several years of follow-up would be required. Accurate 
risk stratification for complications, based on detected laboratory 
toxicity, is hampered by the heterogeneity of data in this study. It is 
unlikely that this will be avoided by a prospective design, as the de-
tection of laboratory toxicity is expected to influence both treatment 
and monitoring. Therefore, a prospective cohort study will probably 
not provide the required data to test this hypothesis.
In conclusion, this study has demonstrated a limited yield of 
current laboratory monitoring practices in maintenance thiopurine 
monotherapy in IBD patients. Firstly, laboratory monitoring in clin-
ical practice was less frequent than advised in current guidelines. 
Secondly, severe myelotoxicity and hepatotoxicity are uncommonly 
detected. Thirdly, this study showed that treating physicians tend 
to disregard aberrant laboratory findings, and were not inclined to 
adjust therapy or perform additional diagnostic evaluation. Finally, 
complications associated with laboratory toxicity occurred rarely, 
and most complications developed unpredictably and could not be 
avoided by frequent monitoring. Reducing laboratory monitoring in 
thiopurine maintenance therapy after 1 year of treatment to less 
than a 4-month interval seems sufficient and could result in reduced 
patient burden and healthcare costs.
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